Drug Profile
XR 11576
Alternative Names: MLN 576Latest Information Update: 09 Feb 2007
Price :
$50
*
At a glance
- Originator Auckland Cancer Society Research Centre; Xenova Group
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Feb 2007 Discontinued - Phase-I for Cancer in Netherlands (PO)
- 09 Feb 2007 Discontinued - Phase-I for Cancer in United Kingdom (PO)
- 05 Apr 2006 No development reported - Phase-I for Cancer in Netherlands (PO)